Pretreatment with AM1241 Enhances the Analgesic Effect of Intrathecally Administrated Mesenchymal Stem Cells

Figure 3

TGF-β1 and p-ERK1/2 expression during the early treatment. (a) Timeline shows the time of BMSC, AM1241, and BMSCs pretreated with AM1241 treatment (CCI day 5) and tissue collection (CCI day 10). (b–g) WB analysis of TGF-β1, p-ERK1/2, ERK1/2, and GAPDH expression after BMSC, AM1241, and BMSCs pretreated with AM1241 injections in the DRGs (b–d) and spinal cord (e–g) in the early phase of treatment. GAPDH was used as the control. , , and versus the sham group; , , and versus the CCI group; , , and versus the BMSCs pretreated with AM1241 group; mice/group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)